E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Standard · 3 min
Ultrasound-assisted preparation of sweet corn cob polysaccharide selenium nanoparticles alleviates symptoms of chronic fatigue syndrome.
Wang, Jingyang, Wang, Xin, Xiu, Weiye et al. · Food & function · 2025 · DOI
Quick Summary
Researchers created tiny particles made from selenium and sweet corn cob material and tested whether they could help reduce fatigue symptoms in mice with chronic fatigue syndrome. The particles appeared to improve energy production in cells and reduce harmful oxidative stress, while also making positive changes to the bacteria in the digestive system.
Why It Matters
This research addresses two key ME/CFS mechanisms—impaired cellular energy production and oxidative stress—by testing a novel therapeutic compound. If these findings translate to human studies, selenium-polysaccharide nanoparticles could represent a new approach to managing core ME/CFS pathology alongside recognized gut dysbiosis.
Observed Findings
U-SCPSeNPs achieved 76.74 nm particle size with 186.83 ± 7.80 mg/g selenium content at 40 minutes ultrasonication.
Treatment enhanced production capacity of Na⁺-K⁺-ATP, Mg²⁺-ATP, and Ca²⁺-ATP in CFS mice.
Antioxidant markers improved: SOD and MDA decreased, while CAT and GSH-Px increased.
Gut microbiota diversity and abundance improved with decreased Firmicutes and increased Bacteroidota phyla.
Sweet corn cob polysaccharides bound to selenium nanoparticles through hydrogen bonding.
Inferred Conclusions
U-SCPSeNPs alleviate CFS-like symptoms in mice by enhancing cellular energy production through ATP-dependent mechanisms.
The nanoparticles reduce oxidative stress burden in CFS disease models.
Polysaccharide-selenium nanoparticles can modulate dysbiotic gut microbiota composition toward a healthier profile.
Ultrasound-assisted synthesis is an effective method for producing bioactive selenium nanoparticles with therapeutic potential.
Remaining Questions
Do U-SCPSeNPs demonstrate similar efficacy and safety in human ME/CFS patients, and at what doses?
What This Study Does Not Prove
This study does not establish that U-SCPSeNPs would be effective or safe in humans with ME/CFS; animal models do not always translate to clinical benefit. The research cannot prove causation of fatigue symptom improvement, only that the particles altered certain biochemical markers in mice. The study does not identify which component (selenium, polysaccharide, or nanoparticle form) drives the observed effects.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →